Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO Sells $86,735.43 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) CFO William Richard White sold 2,817 shares of the stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $30.79, for a total transaction of $86,735.43. Following the transaction, the chief financial officer now directly owns 38,335 shares in the company, valued at approximately $1,180,334.65. This represents a 6.85 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Akero Therapeutics Stock Down 4.3 %

Shares of AKRO stock opened at $29.03 on Friday. Akero Therapeutics, Inc. has a 1-year low of $15.32 and a 1-year high of $37.00. The firm has a fifty day moving average of $30.79 and a two-hundred day moving average of $27.01. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings results on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.15). On average, sell-side analysts anticipate that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Akero Therapeutics in a research note on Monday, November 18th. Citigroup began coverage on shares of Akero Therapeutics in a report on Monday, November 18th. They set a “buy” rating and a $65.00 price target for the company. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Akero Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $46.83.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC boosted its holdings in shares of Akero Therapeutics by 127.9% in the 3rd quarter. Barclays PLC now owns 127,668 shares of the company’s stock valued at $3,662,000 after buying an additional 71,652 shares during the period. Y Intercept Hong Kong Ltd boosted its holdings in shares of Akero Therapeutics by 13.8% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 16,916 shares of the company’s stock valued at $485,000 after buying an additional 2,049 shares during the period. XTX Topco Ltd acquired a new position in shares of Akero Therapeutics in the 3rd quarter valued at about $308,000. Wellington Management Group LLP lifted its position in Akero Therapeutics by 54.4% in the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock valued at $226,554,000 after purchasing an additional 2,782,029 shares during the last quarter. Finally, RTW Investments LP lifted its position in Akero Therapeutics by 9.0% in the 3rd quarter. RTW Investments LP now owns 5,919,435 shares of the company’s stock valued at $169,829,000 after purchasing an additional 487,450 shares during the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.